自身免疫性疾病中的调节性B细胞：见解与治疗潜力。
Regulatory B cells in autoimmune diseases: Insights and therapeutic potential.
作者信息
Su Qin-Yi, Jiang Zhong-Qing, Song Xuan-Yi, Zhang Sheng-Xiao
机构信息
The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; Shanxi Provincial Key Laboratory of Rheumatism Immune Microecology, Shanxi Province, Taiyuan, China; Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Province, Taiyuan, China.
Shanxi Provincial Key Laboratory of Rheumatism Immune Microecology, Shanxi Province, Taiyuan, China; Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Province, Taiyuan, China.
出版信息
J Autoimmun. 2024 Dec;149:103326. doi: 10.1016/j.jaut.2024.103326. Epub 2024 Nov 8.
Autoimmune diseases are characterized by the body's immune system attacking its own cells, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). In recent studies, regulatory B cells (Bregs), which play a vital role in maintaining peripheral tolerance and controlling persistent autoimmune diseases (ADs), have shown great potential in treating ADs. This review synthesizes the latest advancements in targeted therapies for ADs, with a particular emphasis on the subgroups, phenotypic markers, and signal pathways associated with Bregs. Following an examination of these elements, the discussion pivots to innovative Breg-based therapeutic approaches for the management of ADs.
自身免疫性疾病的特征是机体免疫系统攻击自身细胞，如系统性红斑狼疮（SLE）、类风湿性关节炎（RA）和多发性硬化症（MS）。在最近的研究中，调节性B细胞（Bregs）在维持外周免疫耐受和控制持续性自身免疫性疾病（ADs）方面发挥着至关重要的作用，已显示出在治疗ADs方面具有巨大潜力。本综述综合了ADs靶向治疗的最新进展，特别强调了与Bregs相关的亚群、表型标志物和信号通路。在对这些要素进行研究之后，讨论转向基于Bregs的创新治疗方法以管理ADs。
Zotero 插件